Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Saba Capital Management, L.P., a ten percent owner of abrdn Life Sciences Investors NASDAQ:HQL, reported selling shares of common stock in two transactions on September 15 and 16, 2025. The sales amounted to a total value of $38,234, with prices ranging from $13.99 to $14.13. The company, currently valued at $406 million, offers investors a notable 12% dividend yield and has maintained dividend payments for three decades, according to InvestingPro data.
On September 15, Saba Capital sold 700 shares at a price of $14.13 per share. The following day, September 16, the firm sold an additional 2,026 shares at $13.99 each. Following these transactions, Saba Capital Management, L.P. still owns 2,950,781 shares of abrdn Life Sciences Investors. The stock has shown resilience this year, posting a 17% year-to-date return despite challenging market conditions.
The sales were disclosed in a Form 4 filing with the Securities and Exchange Commission. The filing was signed by Zachary Gindes on behalf of Saba Capital Management, L.P., and by Boaz Weinstein. Want deeper insights into HQL’s financial health and dividend sustainability? InvestingPro subscribers get access to over 20 additional financial metrics and analysis tools.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.